Onconova Therapeutics Announces Participation at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference
Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. A corporate overview will be presented by CEO Steven Fruchtman, available from September 13 at 7:00 a.m. ET. Onconova is engaged in clinical-stage development of cancer therapies, including ON 123300 and rigosertib, both undergoing significant studies in the U.S. and China. Forward-looking statements highlight potential risks and uncertainties related to clinical trials and regulatory processes.
- Participation in a recognized investment conference may enhance visibility.
- Ongoing clinical studies for ON 123300 in the U.S. and China signify progress in drug development.
- Investigator-initiated study of rigosertib in combination with nivolumab potentially expands treatment options.
- Forward-looking statements indicate uncertainty regarding the success of clinical trials.
- Risks associated with regulatory approvals and market conditions could affect future performance.
NEWTOWN, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021.
A corporate overview, presented by Steven Fruchtman, M.D., President & CEO of Onconova, will be available to conference participants beginning Monday, September 13th at 7:00 a.m. ET using the following link: https://journey.ct.events/view/68e685c9-2525-4016-b704-7e93cf3d5f9b.
Following the conference, the corporate overview will be available on the “Corporate Events and Presentations” section of the Onconova website.
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.
Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, including in a dose-escalation and expansion Phase 1/2a investigator-initiated study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.
For more information, please visit www.onconova.com.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the timing of Onconova’s and investigator-initiated clinical development and data presentation plans, and the mechanisms and indications for Onconova’s product candidates. Onconova has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “preliminary,” "approximately" or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova's clinical trials, investigator-initiated trials and regulatory agency and institutional review board approvals of protocols, Onconova’s collaborations, the timing of the Company’s annual stockholder meeting, market conditions and those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/
Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com
FAQ
What is Onconova Therapeutics participating in on September 13, 2021?
Who will present Onconova's corporate overview during the conference?
What are Onconova's key products under development?
Where are Onconova's clinical studies for ON 123300 taking place?
What are the risks mentioned in Onconova's press release?
